How does NGMD's PB Ratio compare to its peers?

NGMD has negative equity and a Price-To-Book Ratio (-5.3x) compared to the peer average (4.2x).

How does NGMD's PB Ratio compare vs other companies in the CA Medical Equipment Industry?

NGMD has negative equity and a Price-To-Book Ratio (-5.3x) compared to the North American Medical Equipment industry average (2.5x).

What is NGMD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate NGMD's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of NGMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate NGMD's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

NuGen Medical Devices (TSXV:NGMD) - Stock Price, News & Analysis

NGMD Stock Overview

A specialty medical device company, develops and commercializes novel drug delivery technologies in Europe, Asia, North America, and internationally. More details

NGMD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Negative shareholders equity

Makes less than USD$1m in revenue (CA$347K)

Earnings have declined by 21.3% per year over past 5 years

Shareholders have been diluted in the past year

+ 2 more risks

NuGen Medical Devices Inc. Competitors

Nanalysis Scientific

TSXV:NSCI

CA$43.0m

Therma Bright

TSXV:THRM

CA$11.1m

Aurora Spine

TSXV:ASG

CA$33.3m

Perimeter Medical Imaging AI

TSXV:PINK

CA$56.0m

Price History & Performance

Summary of all time highs, changes and price drops for NuGen Medical Devices
Historical stock prices
Current Share Price	CA$0.09
52 Week High	CA$0.15
52 Week Low	CA$0.08
Beta	2.66
11 Month Change	0%
3 Month Change	-10.00%
1 Year Change	-18.18%
33 Year Change	-72.31%
5 Year Change	n/a
Change since IPO	-70.49%

Recent updates

Shareholder Returns

	NGMD	CA Medical Equipment	CA Market
7D	-10.0%	6.7%	0.4%
1Y	-18.2%	3.7%	21.4%

Return vs Industry: NGMD underperformed the Canadian Medical Equipment industry which returned 3.7% over the past year.

Return vs Market: NGMD underperformed the Canadian Market which returned 21.4% over the past year.

Price Volatility

Is NGMD's price volatile compared to industry and market?
NGMD volatility
NGMD Average Weekly Movement	15.3%
Medical Equipment Industry Average Movement	13.7%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.7%
10% least volatile stocks in CA Market	2.9%

Stable Share Price: NGMD's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: NGMD's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Ian Heynen	www.nugenmd.com

NuGen Medical Devices Inc., a specialty medical device company, develops and commercializes novel drug delivery technologies in Europe, Asia, North America, and internationally. The company offers needle-free injection devices and systems for the administration of subcutaneous medication for various fields, including diabetes, semaglutide, and growth and fertility hormone, as well as DNA and conventional/pediatric vaccines. It also provides InsuJet system that focuses on servicing the diabetic community; and V5, V6, V7, and V8 InsuJet injectors.

NuGen Medical Devices Inc. Fundamentals Summary

How do NuGen Medical Devices's earnings and revenue compare to its market cap?
NGMD fundamental statistics
Market cap	CA$19.60m
Earnings (TTM)	-CA$7.63m
Revenue (TTM)	CA$346.80k

56.5x

P/S Ratio

-2.6x

P/E Ratio

Is NGMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NGMD income statement (TTM)
Revenue	CA$346.80k
Cost of Revenue	CA$176.35k
Gross Profit	CA$170.45k
Other Expenses	CA$7.80m
Earnings	-CA$7.63m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.035
Gross Margin	49.15%
Net Profit Margin	-2,201.33%
Debt/Equity Ratio	-221.0%

How did NGMD perform over the long term?

See historical performance and comparison

NGMD Stock Overview

Risk Analysis

NuGen Medical Devices Inc. Competitors

TSXV:NSCI

CA$43.0m

TSXV:THRM

CA$11.1m

TSXV:ASG

CA$33.3m

TSXV:PINK

CA$56.0m

Price History & Performance

Recent News & Updates

Second quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.015 loss in 2Q 2023)

NuGen Medical Devices Inc. announced that it expects to receive CAD 10 million in funding

NuGen Medical Devices Inc., Annual General Meeting, Aug 20, 2024

First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.017 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.056 loss per share (vs CA$0.062 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in 3Q 2022)

Recent updates

Second quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.015 loss in 2Q 2023)

NuGen Medical Devices Inc. announced that it expects to receive CAD 10 million in funding

NuGen Medical Devices Inc., Annual General Meeting, Aug 20, 2024

First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.017 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.056 loss per share (vs CA$0.062 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in 3Q 2022)

NuGen Medical Devices Inc. Announces Chief Executive Officer Changes

NuGen Medical Devices Inc. Presents New Data from Preliminary Trial That Semaglutide (Ozempic ) Is Chemically Stable After It Is Administered Through Nugen 's InsuJet Needle-Free Injection Device

New major risk - Financial position

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.016 loss in 2Q 2022)

New minor risk - Insider selling

CEO, President & Director exercised options to buy CA$594k worth of stock.

First quarter 2023 earnings released: CA$0.017 loss per share (vs CA$0.017 loss in 1Q 2022)

NuGen Medical Devices Inc. announced that it has received CAD 0.45 million in funding

Full year 2022 earnings released: CA$0.062 loss per share (vs CA$0.10 loss in FY 2021)

NuGen Medical Devices Inc. announced that it has received CAD 2.5 million in funding

NuGen Medical Devices Inc. announced that it has received CAD 0.125 million in funding

Nugen Medical Devices Inc. Announces Executive Changes

NuGen Medical Devices Inc. announced that it expects to receive CAD 3 million in funding

Less than half of directors are independent

Third quarter 2022 earnings released

NuGen Medical Devices Inc. Announces the Launch of Its InsuJet Needle-Free Injection Device in Canada

NuGen Medical Devices Inc. Welcomes Erik Emerson to Its Advisory Board

NuGen Medical Devices Inc. Appoints Greg Gironda to Its Advisory Board

NuGen Medical Devices Inc. announced that it has received CAD 0.640376 million in funding

Second quarter 2022 earnings released: CA$0.016 loss per share (vs CA$0.021 loss in 2Q 2021)

NuGen Medical Devices Inc. announced that it expects to receive CAD 0.4118 million in funding

Nugen M.D. Receives Additional Health Canada Approval for Insulin Specific Needle-Free Injection System

NuGen Medical Devices Inc. Launches PetJet Providing Needle-Free Injections for Domesticated Pets

First quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.013 loss in 1Q 2021)

NuGen Medical Devices Inc., Annual General Meeting, Jun 17, 2022

Independent Director recently bought CA$53k worth of stock

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Independent Director recently bought CA$304k worth of stock